JPRN-UMIN000021793招募中未知
Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trial - Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trial
Department of Hepatology, Osaka Metropolitan University0 个研究点目标入组 90 人开始时间: 2020年12月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. no previous use of other nucleoside analog 2. presence of resistance to nucleoside analog 3. other likely causes of chronic liver disease, such as autoimmune or alcoholic liver disease 4. viable HCC or other malignancies 5. decompensated liver function (Child B or C) 6. severe complication (ex. impaired renal, cardiac or respiratory function) 7. women who are possibly pregnant, expectant mothers, and lactating mothers 8. history of allergy to nucleoside analog
研究者
相似试验
招募中
不适用
Efficacy and safety of switching from entecavir to tenofovir for chronic hepatitis B patients with sustained viral supression: a randomized controlled trialchronic hepatitis BJPRN-UMIN000018406Toranomon Hospital100
已完成
不适用
Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patientsHIV infectionJPRN-UMIN000038177Kyushu University Hospital Department of General internal medicine120
已完成
3 期
Comparative study between Entecavir and Tenofovir in the treatment of chronic hepatitis B infection in Thai patientsChronic hepatitis B infectionChronic hepatitis B,Tenofovir,Entecavir,Efficacy,SafetyTCTR20180626002Chulabhorn Hospital442
招募中
不适用
Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis BChronic hepatitis BJPRN-UMIN000031903Kyushu University400
已完成
3 期
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trialTenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in HIV infected patientsTDF induced nephrotoxicity,switching,virological response,abacavir,lopinavir/ritonavirTCTR20190708002none84